Response by Butt et al to Letter Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial".

Authors :: Butt, Jawad H.
Solomon, Scott D.
McMurray, John J.V.
Source :: Circulation. 4/4/2023, Vol. 147 Issue 14, p1119-1120. 2p.
Publication Year :: 2023
Abstract: Drs Wong and Demers are of course correct that there is an association between frailty and age, but it is also well recognized that frailty can develop at any age. Article Information Disclosures J.H.B. reports advisory board honoraria from Bayer, consultant fees from Novartis, and travel grants from AstraZeneca. [Extracted from the article]

Subjects :: *HEART failure
*HEART failure patients
*FAILURE analysis
*FRAILTY
*DAPAGLIFLOZIN

Full Text Access

Tools